ArticleFrontiers in pharmacology2025
Harnessing natural terpenes via PEGylated mucoadhesive vesicles for improved urinary bladder delivery: from
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Terpesomes as Advanced Nanocarriers for Enhanced Drug Delivery: Formulation Strategies, Mechanistic Insights, and Therapeutic Applications.AAPS PharmSciTech · 2026Review
- β-cyclodextrin-kneaded Coccinia grandis thermosensitive mucoadhesive buccal gel: factorial optimization and preclinical evaluation in cisplatin-induced pica.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Quality by Design-Guided Development of Ketoprofen-Cationic Aspasomes Unlocks the Antifungal Potential of Repurposed Ketoprofen for Topical Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Ruxolitinib phosphate-laden nanoemulgel: amelioration of ex vivo permeation and in vivo therapeutic efficacy for the effective therapeutic management of psoriasis.Inflammopharmacology · 2026Article
- Terpene-Enriched Nitazoxanide-Loaded Chondrosomes: Aerodynamic Characterization and In Silico Evaluation of Antiviral Activity.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fenticonazole nitrate (FTN)-loaded chitosan-coated PEGylated terpesomes (TPs) were investigated as a mucoadhesive formulation to enhance drug delivery to the urinary bladder. Methods: The design of fenticonazole nitrate-loaded terpesome (FTN-TP) formulations was carried out using a 3 Results: The optimized CCPTs exhibited increased entrapment efficiency and zeta potential values without a significant increase in particle size or polydispersity index. They also demonstrated good mucoadhesive properties and remained stable for up to 90 days. Confocal laser scanning microscopy confirmed the penetration of the fluorescently optimized CCPTs through the urinary bladder wall. Conclusion: The optimum formulation could serve as an effective alternative carrier for urinary bladder delivery of fenticonazole nitrate, prolonging its residence time and thereby enhancing its therapeutic pharmacological effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.